Quick Answer
Protagonist Therapeutics, Inc reported Research And Development Expense of $159.29 million for the year ending 2025.
- Protagonist Therapeutics, Inc showed an increase of +15.3% in Research And Development Expense from 2024 to 2025.
- This data is from Protagonist Therapeutics, Inc's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Protagonist Therapeutics, Inc's Research And Development Expense has grown by 2,035.5%.
- Historical annual values: Fiscal year 2025: $159.29 million | Fiscal year 2024: $138.13 million | Fiscal year 2023: $120.16 million | Fiscal year 2022: $126.22 million | Fiscal year 2021: $126.01 million | Fiscal year 2020: $74.51 million | Fiscal year 2019: $65.00 million | Fiscal year 2018: $59.50 million | Fiscal year 2017: $46.18 million | Fiscal year 2016: $25.71 million | Fiscal year 2015: $11.83 million | Fiscal year 2014: $7.46 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: